Abstract:The development of novel therapeutics that exploit alterations in the activation state of key cellular signaling pathways due to mutations in upstream regulators has generated the field of personalized medicine. These first-generation efforts have focused on actionable mutations identified by deep sequencing of large numbers of tumor samples. We propose that a second-generation opportunity exists by exploiting key downstream "nodes of control" that contribute to oncogenesis and are inappropriately activated due to loss of upstream regulation and microenvironmental influences. The RNA-binding protein HuR represents such a node. Because HuR functionality in cancer cells is dependent on HuR dimerization and its nuclear/cytoplasmic shuttling, we developed a new class of molecules targeting HuR protein dimerization. A structure-activity relationship algorithm enabled development of inhibitors of HuR multimer formation that were soluble, had micromolar activity, and penetrated the blood-brain barrier. These inhibitors were evaluated for activity validation and specificity in a robust cell-based assay of HuR dimerization. SRI-42127, a molecule that met these criteria, inhibited HuR multimer formation across primary patient-derived glioblastoma xenolines (PDGx), leading to arrest of proliferation, induction of apoptosis, and inhibition of colony formation. SRI-42127 had favorable attributes with central nervous system penetration and inhibited tumor growth in mouse models. RNA and protein analysis of SRI-42127-treated PDGx xenolines across glioblastoma molecular subtypes confirmed attenuation of targets upregulated by HuR. These results highlight how focusing on key attributes of HuR that contribute to cancer progression, namely cytoplasmic localization and multimerization, has led to the development of a novel, highly effective inhibitor. SIGNIFICANCE: These findings utilize a cell-based mechanism of action assay with a structure-activity relationship compound development pathway to discover inhibitors that target HuR dimerization, a mechanism required for cancer promotion.

Supplementary Data File S2 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Supplementary Data File S6 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Supplementary Data File S1 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Supplementary Data from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Supplementary Data File 3 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Data File 4 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 2 from HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Data File 6 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Materials 2 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Data File 5 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary File 1 from Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy

Supplementary file from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy

Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Supplementary Table 2 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER<sup>+</sup> Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Supplementary Table 1 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER<sup>+</sup> Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes